Latest Amyloid precursor protein secretase Stories
A drug used to treat asthma has been shown to help reduce the formation of amyloid beta, a peptide in the brain that is implicated in the development of Alzheimer's disease.
Mount Sinai School of Medicine researchers have found that a gene associated with the onset of Type 2 diabetes also is found at lower-than-normal levels in people with Alzheimer's disease.
NEW YORK, Sept. 1 /PRNewswire-USNewswire/ -- Researchers at the Fisher Center for Alzheimer's Disease Research laboratory today published "Gamma-secretase Activating Protein is a Therapeutic Target for Alzheimer's Disease" in Nature online. Drs.
HONOLULU, July 14 /PRNewswire/ -- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease (ICAD) results from its proprietary gamma-secretase modulator (GSM) pre-clinical study.
Reducing a protein called beta-amyloid in young mice with a condition resembling Down syndrome improves their ability to learn, researchers at UT Southwestern Medical Center have found.
WATERTOWN, Mass., Dec. 8 /PRNewswire/ -- EnVivo Pharmaceuticals today reported the successful reduction in the levels of aggregated Abeta or Beta-Amyloid in an aged transgenic model (Tg2576) of Alzheimer's disease with its lead gamma-secretase modulator (GSM) EVP-0962.
VIENNA, July 14 /PRNewswire/ -- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) the reversal of behavioral deficits observed in an Alzheimer's disease transgenic animal model after chronic oral dosing of a proprietary gamma-secretase modulator (GSM).
The destructive cellular pathways activated in Alzheimer's disease are also triggered following traumatic brain injury, say researchers from Georgetown University Medical Center
Taking a new approach to the treatment and prevention of Alzheimer's disease, a research team led by investigators at the Mayo Clinic campus in Florida has shown that druglike compounds can speed up destruction of the amyloid beta (A-beta) proteins that form plaque in the brains of patients with the disorder.
PARIS, February 26 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) is pleased to announce that clinical testing of EHT 0202, its lead compound in Alzheimer's disease, is progressing well.
- a slit in a tire to drain away surface water and improve traction.